¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ S=`+Ryc  
<A5 ]]{9 +  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© }x0- V8  
/u%h8!"R  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© ulFzZHJ  
YgUH'P-  
1.Co-stimulators (or co-stimulating molecules) #oeG!<Mn  
h%; e0Xz|  
2.NK-kB fWc|gq  
=J-5.0Q\_\  
3.Immunoglobulin superfamily 7hW+T7u?  
:<Y}l-x  
4.antigen-presenting cell (APC) .nu @ o40  
fKC3-zm  
5.death domain >(w2GD?   
PNF?;*`-{7  
6.CCR and CXCR D\w h;r  
`@d<n  
7.Lectin (or mitogen) uwf 5!Z:>  
E!BPE>  
8.Clusters of differentiation, CD) Aa0b6?Jm  
EN{]Qb06A  
9.B7 family TD[EQ  
|7,L`utp  
10.Cytotoxic T lymphocyte, CTL) sDr/k`>  
}+o:j'jB  
11.IL-15 and IL-15 receptor (IL-15R) k#8Ti"0  
HEL!GC>#  
12.MHC restriction iGB_{F~t4}  
v_e9}yI   
13.Affinity-chromatography [7(-T?_  
1im^17 X  
14.Cyctosprin A, CsA 43?^7_l-  
 Qk!;M |  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) ]E  =Iu  
XwV'Ha  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 4Mk-2 Dx  
5es[Ph|K5  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿  ^p n(=4  
b:qY gg  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ eC5$#,HiC  
tm7u^9]  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ r{L4]|(utY  
iU6Gp-<M ,  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© Fnk_\d6Ma  
`eu9dLz H  
ÃâÒßѧרҵ£º Y#!h9F  
.]aF 1}AI  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ Sa19q.~%  
$gBd <N9|c  
Ïû»¯ÄÚ¿Æ£º (98Nzgxgx}  
''\;z<v   
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ ]*7Y~dO  
<b/~.$a'  
ѪҺ²¡Ñ§×¨Òµ£º s1?[7yC  
wP,JjPUt  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»